These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36109525)

  • 1. SARS-CoV-2 pneumonia and bacterial pneumonia patients differ in a second hit immune response model.
    Moser D; Feuerecker M; Biere K; Han B; Hoerl M; Schelling G; Kaufmann I; Choukér A; Woehrle T
    Sci Rep; 2022 Sep; 12(1):15485. PubMed ID: 36109525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early suppression of peripheral mononuclear blood cells in sepsis in response to stimulation with cytomegalovirus, OKT3, and pokeweed mitogen.
    Malewicz NM; Walstein K; Heine T; Engler A; Bick A; Cox L; Dötsch A; Westendorf AM; Horn PA; Lindemann M; Peters J; Schäfer ST
    J Appl Physiol (1985); 2019 Dec; 127(6):1539-1547. PubMed ID: 31545153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overlapping but Disparate Inflammatory and Immunosuppressive Responses to SARS-CoV-2 and Bacterial Sepsis: An Immunological Time Course Analysis.
    Loftus TJ; Ungaro R; Dirain M; Efron PA; Mazer MB; Remy KE; Hotchkiss RS; Zhong L; Bacher R; Starostik P; Moldawer LL; Brakenridge SC
    Front Immunol; 2021; 12():792448. PubMed ID: 34956225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
    J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison between SARS-CoV-2 and Gram-Negative Bacteria-Induced Hyperinflammation and Sepsis.
    Brandenburg K; Ferrer-Espada R; Martinez-de-Tejada G; Nehls C; Fukuoka S; Mauss K; Weindl G; Garidel P
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.
    Wilson JG; Simpson LJ; Ferreira AM; Rustagi A; Roque J; Asuni A; Ranganath T; Grant PM; Subramanian A; Rosenberg-Hasson Y; Maecker HT; Holmes SP; Levitt JE; Blish CA; Rogers AJ
    JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32706339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunostimulation and Coagulopathy in COVID-19 Compared to Patients With H1N1 Pneumonia or Bacterial Sepsis.
    Papadakis DD; Politou M; Kompoti M; Vagionas D; Kostakou E; Theodoulou D; Kaniaris E; Rovina N; Panayiotakopoulos G; Dimopoulos S; Koutsoukou A; Vasileiadis I
    In Vivo; 2022; 36(2):954-960. PubMed ID: 35241555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of immunological biomarkers in COVID-19 and bacterial pneumonia.
    Abakar MAA; Hamad DHA; Faisal E; Omer HMF; Faki MTM; Idris AEM; Omer R; Osman Z; Elhassan EAG; Abrahim-Holie MA; Hakami MA; Alghamdi A; Alfahed A; Aloraini GS; Alharthi NS; Waggiallah HA
    J Med Life; 2023 Dec; 16(12):1844-1851. PubMed ID: 38585537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with SARS-CoV-2-Induced Viral Sepsis Simultaneously Show Immune Activation, Impaired Immune Function and a Procoagulatory Disease State.
    Limmer A; Engler A; Kattner S; Gregorius J; Pattberg KT; Schulz R; Schwab J; Roth J; Vogl T; Krawczyk A; Witzke O; Zelinskyy G; Dittmer U; Brenner T; Berger MM
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparable cytokine release ex-vivo by whole blood from COVID-19 patients with and without non-invasive ventilation.
    Bonacini M; Ferrigno I; Rossi A; Facciolongo N; Massari M; Corsini R; Galli V; Zerbini A; Salvarani C; Croci S
    Immunobiology; 2023 Nov; 228(6):152755. PubMed ID: 38570901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal dynamics of oropharyngeal microbiome among SARS-CoV-2 patients reveals continued dysbiosis even after Viral Clearance.
    Paine SK; Rout UK; Bhattacharyya C; Parai D; Alam M; Nanda RR; Tripathi D; Choudhury P; Kundu CN; Pati S; Bhattacharya D; Basu A
    NPJ Biofilms Microbiomes; 2022 Aug; 8(1):67. PubMed ID: 36002454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive immunity to SARS-CoV-2 infection: A systematic review.
    Silva MJA; Ribeiro LR; Lima KVB; Lima LNGC
    Front Immunol; 2022; 13():1001198. PubMed ID: 36300105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status.
    Du H; Dong X; Zhang JJ; Cao YY; Akdis M; Huang PQ; Chen HW; Li Y; Liu GH; Akdis CA; Lu XX; Gao YD
    Allergy; 2021 Feb; 76(2):510-532. PubMed ID: 32524611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19.
    Venet F; Gossez M; Bidar F; Bodinier M; Coudereau R; Lukaszewicz AC; Tardiveau C; Brengel-Pesce K; Cheynet V; Cazalis MA; Pescarmona R; Garnier L; Ortillon M; Buisson M; Bouscambert-Duchamp M; Morfin-Sherpa F; Casalegno JS; Conti F; Rimmelé T; Argaud L; Cour M; Saadatian-Elahi M; Henaff L; Vanhems P; Monneret G;
    EBioMedicine; 2022 Apr; 78():103967. PubMed ID: 35349827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation.
    De Bruyn A; Verellen S; Bruckers L; Geebelen L; Callebaut I; De Pauw I; Stessel B; Dubois J
    BMC Infect Dis; 2022 Mar; 22(1):207. PubMed ID: 35236299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reproduction of a model of "two-hit" sepsis model with complication of pneumonia in rat].
    Chen Y; Li H; Ma S; Deng B; Lu J; Ding F
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Oct; 27(10):805-10. PubMed ID: 27132442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.